 | Up a level |
Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel Shao-Weng, Felip, Enriqueta, Chow, Laura Quan Man, Camidge, D. Ross, Vansteenkiste, Johan F., Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin H., Liu, Geoffrey, Santoro, Armando 
ORCID: 0000-0003-1709-9492, Geraldes, Margarida, Boral, Anthony, Yovine, Alejandro Javier and Shaw, Alice Tsang
(2014).
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.
J. Clin. Oncol., 32 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Tan, Daniel Shao-Weng, Shaw, Alice Tsang, Mehra, Ranee, Felip, Enriqueta, Chow, Laura Quan Man, Camidge, D. Ross, Vansteenkiste, Johan F., Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin H., Liu, Geoffrey, Santoro, Armando ORCID: 0000-0003-1709-9492, Geraides, Margarida, Boral, Anthony, Yovine, Alejandro Javier and Kim, Dong-Wan
(2014).
Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) NSCLC: Subgroup analysis of the ASCEND-1 trial.
J. Clin. Oncol., 32 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755